A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Inclusion criteria: * Signed consent obtained before any study-related activities (study-related activities are any pro-cedure related to recording of data according to the protocol). * Are eligible for Wegovy and are due to initiate treatment for the first time within the study period; the decision to initiate treatment with commercially available Wegovy has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. * Male or female, age above or equal to 18 years at time of signing informed consent. * Have at least one reported weight measurement documented at baseline or within 28 days prior to baseline. * Participants must be able to complete the electronic patient reported outcome (ePRO) questionnaires on a compatible electronic device with internet access. * Fulfil the respective reimbursement criteria in the visit prior to / at baseline in Switzerland and United Kingdom (UK). Exclusion criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study. * Presence of a documented refusal or unwillingness to participate in research. * Previous treatment with other obesity management pharmacotherapy or any glucagon like pep-tide-1 (GLP- 1) receptor agonist up to 90 days prior to baseline in Switzerland and UK. * Previous treatment with other obesity management pharmacotherapy or any GLP- 1 receptor agonist up to 30 days prior to baseline in Spain. * Pregnant or women of childbearing potential and not using a highly effective contraceptive method. * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation with the study requirements. * Individuals who have reported plans to move out in the next 12 months to an area not serviced by their current site. * Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) in Spain and UK. * Participant has had a prior serious allergic reaction to semaglutide or any of the ingredients in Wegovy. * Have had Saxenda reimbursed by basic mandatory health insurance for a cumulative period of more than 12 months prior to baseline in Switzerland. * Documented history of diabetes mellitus type 1 and type 2 in Spain. * Presence of diabetic complications and/or at risk of hypoglycaemia (with a documented history of frequent hypoglycaemia) in Spain.